HCP Live
Contagion LiveCGT LiveNeurology LiveHCP LiveOncology LiveContemporary PediatricsContemporary OBGYNEndocrinology NetworkPractical CardiologyRheumatology Netowrk

Women's Health


The Endocrinology Network® Women’s Health clinical resource center is a hub of news and information related to health of women at all ages and stages of life. This page offers perspective and insight on the latest information from multiple fields of women’s health, including gestational diabetes, hormone therapy, menopause management, and reproductive health.

MYFEMBREE Scores FDA Approval for Endometriosis Pain

August 06, 2022

On August 5, Pfizer announced the FDA's approval of relugolix 40 mg, estradiol 1 mg, and norethindrone acetate 0.5 mg (MYFEMBREE) for the management of moderate to severe pain associated with endometriosis in premenopausal women for up to 24 months.

Women's Preventive Services Initiative Releases Guidance for Preventing Obesity in Midlife

August 04, 2022

A national coalition of more than 20 health professional organizations and patient representatives, the WPSI recommendation for preventing obesity in midlife women advocates for counseling to maintain weight or limit weight gain among women with normal or overweight BMI aged 40-60 years.

Endocrine Month in Review: July 2022

July 30, 2022

Our endocrinology month in review spotlights the most popular content from the past month. The top content from July includes hormone therapy guidance from NAMS, a comparison of management practices among Medicare beneficiaries, and a recap of the top approvals from the first half of 2022.

Hormone Replacement Therapy Does Not Increase Breast Cancer Recurrence, Mortality in Survivors

July 20, 2022

An analysis of data from more than 8400 postmenopausal women with a history of early-stage nonmetastatic, ER-positive breast cancer suggests there was no increase in risk of breast cancer recurrence or mortality observed with use of vaginal estrogen therapy or menopausal hormone therapy.

Increased PFAS Exposure Linked to High Blood Pressure in Aging Women

June 18, 2022

According to a new study, cumulative exposure to PFAS during midlife can increase the risk of incident hypertension among women as they age, with those in the highest tertile of cumulative exposure at a 71% greater risk of developing hypertension.

Fezolinetant Reduces Menopause Symptoms, Could Improve Sleep

June 15, 2022

New data from the SKYLIGHT 2 trial demonstrate the reductions in frequency and severity of vasomotor menopausal symptoms in midlife women associated with the use of fezolinetant as well as potential improvements in sleep associated with use of the neurokinin-3 receptor antagonist from Astellas Pharma.

Endocrine Month in Review: April 2022

April 23, 2022

Our endocrine month in review spotlights the most popular articles from the past month. This month's top articles include a multipart video series, new diabetes, information on osteoporosis, and more!